RBC Capital analyst Douglas Miehm raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $11.00 (from $9.00) while maintaining a Outperform rating.

• no surprises out of the results
• remains on track in its Ph. III lupus nephritis trial
• updated model on positive IP developments for voclosporin